Trying on the underlying holdings of the ETFs in our protection universe at ETF Channel, we’ve in contrast the buying and selling worth of every holding towards the typical analyst 12-month ahead goal worth, and computed the weighted common implied analyst goal worth for the ETF itself. For the First Belief NYSE Arca Biotechnology Index Fund ETF (Image: FBT), we discovered that the implied analyst goal worth for the ETF primarily based upon its underlying holdings is $218.78 per unit.
With FBT buying and selling at a current worth close to $169.25 per unit, that signifies that analysts see 29.27% upside for this ETF trying via to the typical analyst targets of the underlying holdings. Three of FBT’s underlying holdings with notable upside to their analyst goal costs are Genmab A/S (Image: GMAB), Acadia Prescription drugs Inc (Image: ACAD), and BioMarin Pharmaceutical Inc (Image: BMRN). Though GMAB has traded at a current worth of $20.51/share, the typical analyst goal is 68.51% greater at $34.56/share. Equally, ACAD has 42.00% upside from the current share worth of $17.50 if the typical analyst goal worth of $24.85/share is reached, and analysts on common predict BMRN to succeed in a goal worth of $96.27/share, which is 38.64% above the current worth of $69.44. Beneath is a twelve month worth historical past chart evaluating the inventory efficiency of GMAB, ACAD, and BMRN:
Mixed, GMAB, ACAD, and BMRN symbolize 9.90% of the First Belief NYSE Arca Biotechnology Index Fund ETF. Beneath is a abstract desk of the present analyst goal costs mentioned above:
| Identify | Image | Current Worth | Avg. Analyst 12-Mo. Goal | % Upside to Goal |
|---|---|---|---|---|
| First Belief NYSE Arca Biotechnology Index Fund ETF | FBT | $169.25 | $218.78 | 29.27% |
| Genmab A/S | GMAB | $20.51 | $34.56 | 68.51% |
| Acadia Prescription drugs Inc | ACAD | $17.50 | $24.85 | 42.00% |
| BioMarin Pharmaceutical Inc | BMRN | $69.44 | $96.27 | 38.64% |
Are analysts justified in these targets, or overly optimistic about the place these shares can be buying and selling 12 months from now? Do the analysts have a legitimate justification for his or her targets, or are they behind the curve on current firm and business developments? A excessive worth goal relative to a inventory’s buying and selling worth can replicate optimism concerning the future, however will also be a precursor to focus on worth downgrades if the targets have been a relic of the previous. These are questions that require additional investor analysis.
10 ETFs With Most Upside To Analyst Targets »
Additionally see:
Home Furnishing Stores Dividend Stocks
PBHC Dividend Growth Rate
Top Ten Hedge Funds Holding LTN
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
